PL377209A1 - Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych - Google Patents

Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych

Info

Publication number
PL377209A1
PL377209A1 PL377209A PL37720903A PL377209A1 PL 377209 A1 PL377209 A1 PL 377209A1 PL 377209 A PL377209 A PL 377209A PL 37720903 A PL37720903 A PL 37720903A PL 377209 A1 PL377209 A1 PL 377209A1
Authority
PL
Poland
Prior art keywords
dendritic cells
tumor
cells
partially matured
administration
Prior art date
Application number
PL377209A
Other languages
English (en)
Inventor
Marnix L. Bosch
Original Assignee
Northwest Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics, Inc. filed Critical Northwest Biotherapeutics, Inc.
Publication of PL377209A1 publication Critical patent/PL377209A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL377209A 2002-12-06 2003-12-05 Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych PL377209A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43126702P 2002-12-06 2002-12-06

Publications (1)

Publication Number Publication Date
PL377209A1 true PL377209A1 (pl) 2006-01-23

Family

ID=32507696

Family Applications (1)

Application Number Title Priority Date Filing Date
PL377209A PL377209A1 (pl) 2002-12-06 2003-12-05 Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych

Country Status (18)

Country Link
US (2) US20060057120A1 (pl)
EP (2) EP1567155B1 (pl)
JP (2) JP4859169B2 (pl)
KR (1) KR101144196B1 (pl)
CN (2) CN102600461B (pl)
AT (1) ATE486125T1 (pl)
AU (2) AU2003293411B2 (pl)
BR (1) BRPI0317064B8 (pl)
CA (1) CA2509058A1 (pl)
DE (1) DE60334725D1 (pl)
DK (1) DK1567155T3 (pl)
ES (1) ES2354944T3 (pl)
IL (1) IL169002A (pl)
MX (1) MXPA05006042A (pl)
PL (1) PL377209A1 (pl)
PT (1) PT1567155E (pl)
RU (1) RU2348418C2 (pl)
WO (1) WO2004053072A2 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1720567A2 (en) * 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
US8076132B2 (en) 2004-09-17 2011-12-13 Hasumi International Research Foundation Dendritic cell tumor injection (DCTI) therapy
US20060216269A1 (en) * 2004-09-17 2006-09-28 Kenichiro Hasumi Dendritic cell tumor injection (DCTI) therapy
US8420078B2 (en) * 2005-03-10 2013-04-16 Yeda Research And Development Co. Ltd. Methods and immunogenic cell preparations for treating antigen-associated diseases
WO2007001200A1 (en) * 2005-06-23 2007-01-04 Obschestvo S Ogranichennoi Otvetsvennostyu 'rusgen' Mature dendritic cells loaded with tumor polylysates and antitumoral vaccine base thereon
AR060424A1 (es) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
WO2008133595A1 (en) * 2007-04-26 2008-11-06 Newbiomed Pika Pte Ltd Compositions and methods for stimulating an immune response in-vivo and in-vitro
WO2008151389A1 (en) * 2007-06-15 2008-12-18 Macfarlane Burnet Institute For Medical Research And Public Health Limited Chemically modified macromolecules
EP2072617A1 (en) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Method for producing dendritic cells
RU2361598C1 (ru) * 2008-02-18 2009-07-20 Тихоокеанский Институт Биоорганической Химии Дальневосточного Отделения Российской Академии Наук (Тибох Дво Ран) Средство, индуцирующее созревание дендритных клеток
CA2718438C (en) * 2008-03-27 2021-06-29 Geron Corporation Differentiation of primate pluripotent stem cells to hematopoietic lineage cells
EP3150703A1 (en) * 2009-07-09 2017-04-05 TiGenix, S.A.U. Cells for use in a method for treating inflammatory and/or immune disorders
PL2534242T3 (pl) * 2010-02-10 2016-11-30 Polepszona kompozycja do hamowania proliferacji komórek nowotworowych
RU2575978C2 (ru) * 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
RU2530523C2 (ru) * 2012-03-29 2014-10-10 Олег Борисович Егоров Способ противоопухолевой иммунотерапии
US8961957B2 (en) 2012-06-27 2015-02-24 Hasumi International Research Foundation Therapy and method for intratumorally introducing cytotoxic T lymphocyte and/or NKT cell with anti-TNF and/or anti-IL-10
GB201300049D0 (en) * 2013-01-03 2013-02-20 Transimmune Ag Method for obtaining immuno-stimulatory dendritic cells
IL292510A (en) 2013-11-05 2022-06-01 Cognate Bioservices Inc Combinations of checkpoint inhibitors and therapeutics to treat cancer
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
IL256522B2 (en) 2015-06-30 2024-10-01 Northwest Biotherapeutics Inc Optimally activated dendritic cells that result in an enhanced or enhanced antitumor immune response
RU2749610C2 (ru) * 2015-09-15 2021-06-16 Нортвест Байотерапьютикс, Инк. Способы, относящиеся к композициям активированных дендритных клеток и к иммунотерапевтическому лечению индивидуумов с прогрессирующим раком
KR101749165B1 (ko) * 2016-06-07 2017-06-23 충남대학교산학협력단 Rv2299c 또는 Rv2299c와 ESAT-6 융합한 단백질을 포함하는 수지상 세포의 성숙화 촉진용 조성물
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
GB201711379D0 (en) * 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
CN109957548B (zh) * 2017-12-26 2022-03-18 上海尚泰生物技术有限公司 一种基因修饰的树突状细胞疫苗
CN116637180A (zh) * 2022-02-15 2023-08-25 沈阳药科大学 萜类化合物在提高其淋巴靶向作用中的应用
GB2624871A (en) * 2022-11-29 2024-06-05 Alv B As Process for preparing a population of dendritic cells and immunotherapy using the same
WO2025052001A1 (en) 2023-09-07 2025-03-13 Mnemo Therapeutics Methods and compositions for improving immune response
EP4520334A1 (en) 2023-09-07 2025-03-12 Mnemo Therapeutics Methods and compositions for improving immune response

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
DE69333433T2 (de) 1992-04-01 2004-12-02 The Rockefeller University Verfahren zur in vitro kultivierung dendritischer vorläuferzellen und deren verwendung zur immunogen herstellung
US5788963A (en) * 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
CA2343355A1 (en) * 1998-09-15 2000-03-23 University Of Pittsburgh Of The Commonwealth System Of Higher Education In situ injection of antigen-presenting cells with genetically enhanced cytokine expression
EP1126023A4 (en) * 1998-10-02 2005-02-16 Mitsubishi Chem Corp METHOD FOR THE INDUCTION OF CELLULAR IMMUNITY AND CELLS WITH INDUCED CELLULAR IMMUNITY
US6649158B1 (en) * 1998-10-15 2003-11-18 Canji, Inc. Methods and compositions to induce antitumor response
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
CN1367688A (zh) * 1999-04-14 2002-09-04 美国政府卫生与公众服务部 用于诱导对移植物的免疫耐受性的、包含免疫毒素和抑制树突细胞成熟的因子的组合物
AU2403901A (en) * 1999-12-28 2001-07-09 Ichiro Azuma Maturation-promoting agent for immature dendritic cells
US20030175247A1 (en) * 2000-05-12 2003-09-18 Michael Salgaller Method to increase class I presentation of exogenous antigens by human dendritic cells
JP2002069001A (ja) * 2000-08-29 2002-03-08 Asahi Kasei Corp 樹状細胞を主成分とする細胞ワクチン
US7405076B2 (en) * 2000-11-14 2008-07-29 Universite Libre De Bruxelles Generation and use of dendritic cells
US20020094545A1 (en) 2000-11-30 2002-07-18 Harris Paul E. Growth of human dendritic cells for cancer immunotherapy in closed system using microcarrier beads
AU2002326463A1 (en) 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors
CA2459713C (en) * 2001-09-06 2015-08-18 Northwest Biotherapeutics, Inc. Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
RU2364625C2 (ru) * 2003-02-27 2009-08-20 Норсуэст Байотерапьютикс, Инк. Генерирование дендритных клеток из моноцитарных предшественников дендритных клеток с помощью gm-csf в отсутствие дополнительных цитокинов

Also Published As

Publication number Publication date
KR20050084189A (ko) 2005-08-26
KR101144196B1 (ko) 2012-05-21
JP2006510667A (ja) 2006-03-30
EP1567155A2 (en) 2005-08-31
ES2354944T3 (es) 2011-03-21
RU2348418C2 (ru) 2009-03-10
WO2004053072A2 (en) 2004-06-24
JP4859169B2 (ja) 2012-01-25
AU2011200352B2 (en) 2013-06-27
US20120251561A1 (en) 2012-10-04
EP2260861A1 (en) 2010-12-15
BRPI0317064B1 (pt) 2020-11-03
CA2509058A1 (en) 2004-06-24
RU2005121256A (ru) 2006-02-10
CN102600461B (zh) 2017-07-14
MXPA05006042A (es) 2005-09-21
AU2003293411A1 (en) 2004-06-30
HK1082180A1 (en) 2006-06-02
DE60334725D1 (de) 2010-12-09
BR0317064A (pt) 2005-10-25
CN1738619B (zh) 2012-04-18
EP1567155A4 (en) 2006-12-13
US20060057120A1 (en) 2006-03-16
PT1567155E (pt) 2011-01-28
CN102600461A (zh) 2012-07-25
AU2003293411B2 (en) 2010-10-28
AU2011200352A1 (en) 2011-02-17
JP2011246493A (ja) 2011-12-08
IL169002A (en) 2015-01-29
BRPI0317064B8 (pt) 2021-05-25
DK1567155T3 (da) 2011-02-14
WO2004053072A3 (en) 2005-06-16
ATE486125T1 (de) 2010-11-15
EP1567155B1 (en) 2010-10-27
CN1738619A (zh) 2006-02-22
JP5707284B2 (ja) 2015-04-30

Similar Documents

Publication Publication Date Title
PL377209A1 (pl) Leczenie nowotworów poprzez podawanie pacjentom częściowo dojrzałych in vitro komórek dendrytycznych
Libraty et al. Interferon-gamma differentially regulates interleukin-12 and interleukin-10 production in leprosy.
Bilsborough et al. Mucosal CD8α+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties
Grabbe et al. Tumor antigen presentation by epidermal antigen‐presenting cells in the mouse: modulation by granulocyte‐macrophage colony‐stimulating factor, tumor necrosis factor α, and ultraviolet radiation
CA2483012A1 (en) Oligonucleotide compositions and their use for the modulation of immune responses
Salio et al. Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells
Handel-Fernandez et al. Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-γ production in mammary tumor-bearing mice
CA2259140A1 (en) Method of activating dendritic cells
Waltenbaugh et al. Alcohol consumption alters antigen‐specific Th1 responses: mechanisms of deficit and repair
DK0668781T3 (da) Lymfokingenterapi af cancer i kombination med tumorantigener
FI933862A0 (fi) Loesliga ligander foer cd40
DK1225870T3 (da) Sammensætning og fremgangsmåde til cancerantigenimmunterapi
DE69839273D1 (de) Krebs immuntherapie mit semi-allogenen zellen
WO2002036141A3 (en) Method of enhancing lymphocyte-mediated immune responses
Sato et al. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK‐432 combined with prostaglandin E2
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
MX2023001622A (es) Celulas dendriticas optimamente activadas que inducen una respuesta inmunologica antitumoral mayor o mejorada.
Mazzoccoli et al. Immune system alterations in lung cancer patients
NZ507829A (en) Vaccine adjuvants for immunotherapy of melanoma
Holzer et al. Haptens as drugs: contact allergens are powerful topical immunomodulators
YU40796A (sh) Preparati i postupci za tretiranje obolenja koja izazivaju t ćelije
MXPA04001872A (es) Modelo de exposicion a micoplasma bovis, procedimiento para administrar m. bovis y procedimientos para inducir lesiones pulmonares neumonicas.
Gelfand Essential role of T lymphocytes in the development of allergen-driven airway hyperresponsiveness
Harada et al. Role of the endogenous production of interleukin 12 in immunotherapy
WO2002015915A3 (en) Method for inducing an anti-tumor and anti-cachexia immune response in mammals

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)